Sponsor:
Hartford Hospital
Code:
NCT05224089
Conditions
Bowel Disease
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Liposomal Bupivicaine/Bupivacaine Admixture
Bupivacaine HCL
Brief summary:
Conditions
Bowel Disease
Study ID
NCT05224089
Start date
Apr 27, 2022
Status verified date
Mar, 2025
Completion date
Feb, 2026
Anticipated
Primary completion date
Nov, 2025
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
114 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: Liposomal Bupivacaine/Bupivacaine HCL
active comparator: Regular Bupivacaine Arm
Interventions
Liposomal Bupivicaine/Bupivacaine Admixture
Bupivacaine HCL
Primary outcome measure
Central contacts
Locations
Hartford Hospital
Recruiting
Hartford, Connecticut, United States, 06102
Contacts
Kevin J Finkel, MD
kevin.finkel@hhchealth.orgSponsor
Hartford Hospital
Last update posted
Apr 2, 2025
Last verified
Mar, 2025
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Hartford Hospital on 2025-04-02.